Pinos Elisabet de los - 01 Feb 2024 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Julie Feder, as Attorney-in-Fact
Issuer symbol
AURA
Transactions as of
01 Feb 2024
Net transactions value
$0
Form type
4
Filing time
02 Feb 2024, 16:01:09 UTC
Previous filing
24 Jan 2024
Next filing
01 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +162,935 +101% $0.000000 324,373 01 Feb 2024 Direct F1
holding AURA Common Stock 131,412 01 Feb 2024 By EdIP Revocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award $0 +237,065 $0.000000 237,065 01 Feb 2024 Common Stock 237,065 $7.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date.
F2 The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
F3 The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

President and Chief Executive Officer